Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01971385 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01971385: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01971385 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01971385, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Subjects with a history of recurrent herpes labialis will be sensitized with either 2% SADBE or placebo. Following this, subjects sensitized with 2% SADBE will received.2% sqauric acid or.5% squaric acid on their cold sore within 72 hours of a recurrence. Subjects sensitized with placebo solution will receive placebo solution on their cold sore within 72 hours of a recurrence. Subjects will be followed for up to 6 mos after application of study medication.
Interventions
- DRUG Placebo solution
- DRUG Squaric Acid solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01971385
The ClinicalTrials.gov registry entry for NCT01971385 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo solution is the first listed.
NCT01971385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01971385 about?
NCT01971385 is a clinical study titled "Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis". Subjects with a history of recurrent herpes labialis will be sensitized with either 2% SADBE or placebo. Following this, subjects sensitized with 2% SADBE will received.2% sqauric acid or.5% squaric acid on their cold sore within 72 hours of a recurrence. Subjects sensitized with placebo solution wi...
What is the current status of trial NCT01971385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2013-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01971385?
The interventions under investigation include: Placebo solution (DRUG), Squaric Acid solution (DRUG).
Who is sponsoring clinical trial NCT01971385?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.